Optical Coherence Tomography (OCT) in Uveitis

February 8, 2024 updated by: David Huang, Oregon Health and Science University

Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography

Optical Coherence Tomography (OCT) machines are non-contact instruments that can provide micrometer (one one-thousandths) scale imaging of biological tissue. This allows excellent assessment of the white blood and inflammatory cells seen in uveitis, an inflammation of any or all parts of the uvea (iris, ciliary body, choroid).

Study Overview

Status

Recruiting

Conditions

Detailed Description

In uveitis, white blood and inflammatory cells can enter the anterior chamber of the eye and adhere to the back surface of the cornea or enter the space between the lens and the retina in various types of uveitis. Transparency of the clear fluid that fills the space between the cornea and the lens (or between the lens and the retina) can be reduced due to the inflammation reaction of the eye. The amounts of these cells and reduced transparency that are present indicate the level of severity of inflammation.

The primary goal of this study is to use OCT to standardize anterior chamber (AC) cell grading. Another goal is to discover whether the size of cells and particles in the AC measured by OCT differs between uveitis diagnostic categories. OCT will also be used to detect protein concentration increases within the clear fluid inside the eye and determine if the concentration increase correlates with findings from the usual slit lamp grading method.

Background data including age, sex, medical history, and eye history will be gathered prior to the study/OCT testing visit. Other standard-of-care testing, like visual acuity and slit lamp (biomicroscope) exam will be performed to see if there is evidence of uveitis that meets the inclusion criteria for this study. If so, grading of the eye inflammation will be performed as defined by the Standardization of Uveitis Nomenclature (SUN). Once enrolled in the study, subjects will then undergo OCT testing with the study device to assess AC cells, AC flare (increased protein), keratic precipitates (cells adhered to back surface of cornea), and vitreous cells & haze (increased opacities in vitreous gel).

OCT Procedure: The subject will be seated and have their head positioned on a chin rest. They will be asked to look at a target (a lighted spot) while a beam of light scans the front part of the eye. The light is infrared and will not be visible or cause any sensation. A cotton tip swab may be used to help hold the eyelid open temporarily if necessary.

Study Type

Observational

Enrollment (Estimated)

75

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Oregon
      • Portland, Oregon, United States, 97239
        • Recruiting
        • Oregon Health & Science University
        • Contact:
        • Sub-Investigator:
          • Eric Suhler, MD
        • Contact:
        • Sub-Investigator:
          • Yan Li, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study will enroll both males and females and include all ethnic and racial groups through clinical practices. The study will enroll subjects 18 years of age or older with physician-confirmed, active uveitis. A total of thirty subjects will be recruited.

Description

Inclusion Criteria:

  • 18 years of age and older
  • With one or more of the following clinical features:

    1. >1+ AC cells;
    2. >1+ vitreous haze;
    3. presence of vitreous cells;
    4. presence of blood in anterior chamber;
    5. presence of blood in vitreous;
    6. presence of aqueous or vitreous pigment.
  • In one of the following diagnostic categories as determined by a uveitis specialists:

    1. uveitis due to ankylosing spondylitis (positive HLA B27 genotype);
    2. uveitis due to sarcoidosis;
    3. uveitis of any additional type;
    4. uveitis masquerade such as pigment dispersion syndrome or Schaffer's sign;
    5. hyphema due to trauma or other causes;
    6. vitreous hemorrhage;
    7. retinal tear.

Exclusion Criteria:

  • Inability to give informed consent;
  • Inability to maintain stable fixation for OCT imaging.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Active Uveitis
Physician-confirmed diagnosis of uveitis of any origin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of anterior chamber cells
Time Frame: 1 month
Anterior chamber cells will be identified from OCT images by computer algorithms. Anterior chamber cells will be measured in particles.
1 month
Number of keratic precipitates (KP)
Time Frame: 1 month
KPs will be identified from OCT images by computer algorithms. KPs will be measured in particles.
1 month
Number of vitreous cells
Time Frame: 1 month
Vitreous cells will be identified from OCT images by computer algorithms. Vitreous cells will be measured in particles.
1 month
Degree of anterior chamber flare
Time Frame: 1 month
OCT signal of the aqueous humor will be analyzed and correlated with slit lamp grades on AC flare. AC flare will be measured in a.u.
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David Huang, MD, PhD, Oregon Health and Science University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

December 30, 2013

First Submitted That Met QC Criteria

December 30, 2013

First Posted (Estimated)

January 1, 2014

Study Record Updates

Last Update Posted (Actual)

February 12, 2024

Last Update Submitted That Met QC Criteria

February 8, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OHSU IRB#00008052

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Uveitis

3
Subscribe